D Kontoyiannis Selected Research

Antifungal Agents

10/2005

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Kontoyiannis Research Topics

Disease

3	Infections 01/2007 - 09/2002
1	Aspergillosis 01/2007
1	Candidemia 10/2005
1	Opportunistic Infections (Opportunistic Infection) 09/2002
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2002
1	Pneumonia (Pneumonitis) 08/2001
1	Respiratory Syncytial Virus Infections 08/2001
1	Respiratory Insufficiency (Respiratory Failure) 08/2001
1	Breast Neoplasms (Breast Cancer) 08/2001
1	Adenoviridae Infections (Adenovirus Infections) 03/2001
1	Lupus Nephritis 07/2000

Drug/Important Bio-Agent (IBA)

1	Caspofungin (Cancidas)FDA Link 01/2007
1	Antifungal AgentsIBA 10/2005
1	EchinocandinsIBA 10/2005
1	Micafungin (FK463)FDA Link 10/2005
1	purineIBA 09/2002
1	fludarabine phosphate (Fludara)FDA LinkGeneric 09/2002
1	AcidsIBA 09/2002
1	fludarabineIBA 09/2002
1	Ribavirin (Virazole)FDA LinkGeneric 08/2001
1	Immunoglobulins (Immunoglobulin)IBA 08/2001
1	Intravenous Immunoglobulins (IVIG)FDA Link 08/2001
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2000

Therapy/Procedure

3	Therapeutics 01/2007 - 03/2001
1	Salvage Therapy 09/2002
1	Transplantation 08/2001